Clinical Trial

A Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical Practice

Study acronym: IMreal
Completed
View on ClinicalTrials.gov →
Summary
This is a non-interventional, multi-country, multi-centre, multiple cohort prospective study, with retrospective collection of prior medical/treatment history data from medical records, designed to assess the real-world outcomes and safety of atezolizumab for indications in the existing label in the real world setting of routine clinical practice.
Protocol Amendment History 1 change
critical Trial completed 2026-08-14
Trial Details
NCT Number NCT03782207
Lead Sponsor Hoffmann-La Roche
Conditions Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Hepatocellular Carcinoma
Enrollment 2,756 participants
Start Date 2019-02-07
Primary Completion 2026-07-31 (estimated)
Study Completion 2026-07-31 (estimated)
Updated on ClinicalTrials.gov 2026-08-13